Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer
|
|
- Arthur Barton
- 6 years ago
- Views:
Transcription
1 JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(10) doi: /jjco/hyw098 Advance Access Publication Date: 18 July 2016 Original Article Original Article Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer Masaki Shiota 1, Akira Yokomizo 1, *, Ario Takeuchi 1, Junichi Inokuchi 1, Katsunori Tatsugami 1, Saiji Ohga 2, Tomonari Sasaki 2, Katsumasa Nakamura 2, Hiroshi Honda 2, and Masatoshi Eto 1 1 Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, and 2 Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan *For reprints and all correspondence: Akira Yokomizo, Department of Urology, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka , Japan. yokoa@uro.med.kyushu-u.ac.jp Received 14 April 2016; Accepted 24 June 2016 Abstract Objective: Although it is well known that radiotherapy for prostate cancer increases comorbid rate of secondary bladder cancer, the effect of aging and smoking with radiotherapy on incidence rate of secondary bladder cancer remains unknown. Then, this study investigated the combinational effect of external beam radiotherapy for prostate cancer and aging or smoking on comorbid rate of secondary bladder cancer. Methods: This study included 754 Japanese patients with prostate cancer treated with radiotherapy (n = 319) and radical prostatectomy (n = 435) from 2000 through The relationship between therapeutic modality for prostate cancer as well as age or smoking status and comorbid rate of secondary bladder cancer was examined. Results: During the median follow-up period of 4.3 and 3.1 years, secondary bladder cancer occurred in 11 (3.4%) and 5 (1.1%) of patients with prostate cancer treated with external beam radiotherapy and radical prostatectomy, respectively. The 5-year bladder cancer-free survival rate was 97.3% in the external beam radiotherapy group and 99.4% in the radical prostatectomy group. Age (hazard ratio = 1.15, P = 0.027) and ever smoking (hazard ratio = 5.65, P = 0.011) were significant predictive factors of secondary bladder cancer incidence in the external beam radiotherapy cohort, but not in the radical prostatectomy cohort. Inversely, among men with ever smoking, but not among older men, external beam radiotherapy (hazard ratio = 9.64, P = ) was a significant risk factor of secondary bladder cancer. Conclusions: Taken together, these findings suggest that smoking history might be one of criteria to choose radical prostatectomy than external beam radiotherapy for prostate cancer, and that age would not be a criterion for therapeutic selection in terms of secondary bladder cancer. Key words: bladder cancer, prostate cancer, radical prostatectomy, radiotherapy, secondary cancer Introduction Prostate cancer is one of the most common cancers among men of developed countries. In USA, it is estimated that ~ men will develop prostate cancer and ~ men will die from prostate cancer in 2015 (1). In Japan, the incidence rate of prostate cancer has been increasing due to various reasons, including the growing prevalence of a Western-style diet and lifestyle and an increase in the aging population as well as prostate-specific antigen (PSA) screening (2). The Author Published by Oxford University Press. All rights reserved. For permissions, please journals.permissions@oup.com 952
2 Jpn J Clin Oncol, 2016, Vol. 46, No Several therapeutic modalities for prostate cancer are available and have been applied to patients according to various clinicopathological parameters and physicians or patients favor. Standard treatment options for localized prostate cancer include radical prostatectomy (RP) by open RP, laparoscopic RP or robot-assisted laparoscopic RP; prostate radiotherapy by external beam radiotherapy (EBRT) and/or brachytherapy; active surveillance; cryotherapy; and androgen deprivation therapy (ADT). Among these therapeutic modalities, physicians and patients can choose the best single option or combination. Due to longer life expectancy in patients with localized prostate cancer, late-phase adverse events are more meaningful and significant. Among late-phase adverse events, secondary cancer could be the most harmful or lethal event because of its aggressive characteristics and limited therapeutic options. In particular, the comorbid rate of secondary bladder cancer (BC) is increased after radiotherapy for prostate cancer (3 10). We recently reported that the incidence of secondary BC increased after radiotherapy, especially EBRT compared with marginally RP and significantly ADT (11). Common risk factors for BC incidence such as aging (12), gender (13) and smoking history (14), in addition to several uncommon risk factors including genetic factors, occupational exposures, water arsenic, Schistosoma haematobium infection and some medications, have been reported (15). Although EBRT would increase the risk of secondary BC, other common risk factors that may affect secondary BC after EBRT have not been well defined. Therefore, in this study, we investigated the effect of known BC-promoting factors including therapeutic modality (EBRT vs. RP) for prostate cancer, age, and smoking status on incidence rate of secondary BC. Patients and methods This study enrolled patients with prostate cancer treated by EBRT or RP at Kyushu University Hospital (Fukuoka, Japan) from 2000 to 2013, among whom smoking status data were available. Ever smoking was defined as former or current smoking experience while current smoking was defined as men with smoking habit at time of diagnosis as prostate cancer. This study was approved by the institutional review board. All patients were histopathologically diagnosed with adenocarcinoma of the prostate. Patients with <1-year follow-up after therapy were excluded. Secondary BC was defined as primary BC diagnosed after 1 year from prostate cancer diagnosis. Thus, cases with preceding BC, concurrent BC, and subsequent BC within 1 year from the diagnosis of prostate cancer as well as recurrent BC were excluded. Clinical staging was determined in accordance with the unified TNM criteria based on the results of a digital rectal examination, transrectal ultrasound, magnetic resonance imaging, computed tomography and bone scan (16). Most patients also underwent cystoscopy to determine tumor extension and to rule out comorbid BC. Patients in EBRT series were treated by EBRT with or without neoadjuvant/adjuvant ADT (more than 3 months) by surgical castration or medical castration using a luteinizing hormonereleasing hormone agonist (goserelin acetate or leuprorelin acetate) and/or an antiandrogen agent (bicalutamide, flutamide or chlormadinone acetate) (17,18). EBRT was performed with a median 72 Gy to the prostate only (n = 275, 86.4%) or the prostate and pelvis (n = 37, 11.6%) by conformal (n = 275, 86.2%) or intensitymodulated radiotherapy (n = 38, 11.9%). Patients in the RP series were treated by open RP (n = 185, 42.5%), laparoscopic RP (n = 67, 15.4%) or robot-assisted laparoscopic RP (n = 183, 42.1%) with or without ADT (19). The cases treated with adjuvant or salvage radiotherapy were excluded from RP series. Patients were followed up during or after treatment for prostate cancer at intervals of ~3 6 months with medical interview, urinalysis and blood test. If BC incidence was suspected, further examinations such as urine cytology and cystoscopy were performed. The time to development of secondary cancer was defined as the duration from starting date of EBRT or operation date to the date of pathological diagnosis of secondary cancer. All secondary BC were histologically confirmed. Pathological evaluation of BC was performed according to 2004 World Health Organization grading (20). All statistical analyses were performed using JMP9 software (SAS Institute, Cary, NC, USA). The secondary BC-free rates were determined using the Kaplan Meier method and the logrank statistic was used to compare survival duration across groups. Comparisons between groups were analyzed by Wilcoxon or Pearson tests. P values <0.05 were considered significant. Results This study enrolled a total of 754 patients, and the clinical and pathological characteristics are shown in Table 1. The median age of patients was 71 and 65 years and the median PSA at diagnosis was 11.0 and 7.8 ng/ml in the EBRT and RP groups, respectively. Advanced clinical T-stage in the EBRT group (ct3/4, 33.2%) was more frequent compared with the RP group (ct3/4, 1.4%). The Gleason scores of biopsy specimens from 91 (29.2%), 133 (42.6%) and 88 (28.2%) patients and 164 (36.4%), 201 (49.1%) and 62 (14.5%) patients were <7, =7 and >7 in those treated with EBRT and RP, respectively. Thus, compared with patients treated with RP, patients treated with EBRT were older and had worse characteristics, such as higher PSA values at diagnosis, higher Gleason scores and more progressive T-stage. During the median follow-up period of 4.3 years (interquartile range [IQR], ) in patients treated with radiotherapy, 11 men (3.4%) were diagnosed with secondary BC. Conversely, during the median follow-up period of 3.1 years (IQR, ) in patients treated with surgical treatment, 5 (1.1%) men were diagnosed with Table 1. Patient characteristics in both cohorts Variable EBRT (n = 319) RP (n = 435) P value Median age, years (IQR) 71 (67 76) 65 (60 69) < a Median PSA at diagnosis, 11.0 ( ) 7.8 ( ) < a ng/ml (IQR) NA 2 0 Clinical T-stage, n (%) ct1 130 (41.1%) 240 (60.4%) ct2 81 (25.6%) 166 (38.2%) ct3 94 (29.7%) 9 (1.4%) ct4 11 (3.5%) 0 (0%) < a NA 3 20 Biopsy Gleason score, n (%) <7 91 (29.2%) 164 (36.4%) (42.6%) 201 (49.1%) 8 88 (28.2%) 62 (14.5%) < a NA 7 8 NA, not available; EBRT, external beam radiotherapy; RP, radical prostatectomy; IQR, interquartile range; PSA, prostate-specific antigen. a Statistically significant.
3 954 Smoking effect on secondary bladder cancer secondary BC. Accordingly, the 5-year BC-free survival rate was 97.3%, and 99.4% among patients treated with EBRT and RP, respectively. When age, ever smoking, current smoking and therapeutic modality were analyzed in incidence of secondary BC among both EBRT and RP cohorts, age (hazard ratio (HR) [95% confidence interval (CI)] = 1.17 [ ], P = 0.006) and ever smoking (HR [95% CI] = 3.11 [ ], P = 0.028) were significantly associated with increased risk of secondary BC, although EBRT (HR [95% CI] = 2.62 [ ], P = 0.064) marginally increased secondary BC risk (Table 2, Supplementary Fig. 1A). As well, former smoking was a significant risk factor of secondary BC compared with never smoking (HR [95% CI] = 4.22 [ ], P = ). However, current smoking (HR [95% CI] = 0.72 [ ], P = 0.65) was not associated with the incidence of secondary BC (Table 2, Supplementary Fig. 1B). The incidence of secondary BC were 5 (1.2%), 9 (4.0%) and 2 (1.6%) cases among 404 never smokers, 225 former smokers and 125 current smokers, respectively. When analyzed in the EBRT cohort, age (HR [95% CI] = 1.15 [ ], P = 0.027) and ever smoking (HR [95% CI] = 5.65 [ ], P = 0.011) were significant risk factors of secondary BC while current smoking (HR [95% CI] = 0.46 [ ], P = 0.12) was not (Table 2, Fig.1A and B). As well, former smoking was a significant risk factor of secondary BC compared with never smoking in the EBRT cohort (HR [95% CI] = 8.38 [ ], P = ). The incidence of secondary BC in the EBRT cohort were 2 (1.1%), 8 (8.8%) and 1 (1.9%) cases among 176 never smokers, 91 former smokers and 52 current smokers, respectively. On multivariate analysis using age and ever smoking as variables, both age (HR [95% CI] = 1.16 [ ], P = 0.016) and ever smoking (HR [95% CI] = 6.09 [ ], P = ) were significant risk factors of secondary BC when treated with EBRT. However, both ever smoking (HR [95% CI] = 0.93 [ ], P = 0.94) and current smoking (HR [95% CI] = 1.29 [ ], P = 0.82) did not affect the comorbid rate of secondary BC in the RP cohort whereas age did marginally affect the comorbid rate (HR [95% CI] = 1.18 [ ], P = 0.062; Table 2, Fig.1C and D). Finally, the impact of therapeutic modality on the risk of secondary BC among men with ever smoking was analyzed. The results showed that age (HR [95% CI] = 1.18 [ ], P = ) and EBRT (HR [95% CI] = 9.64 [ ], P = ) were significant risk factors of secondary BC among ever smokers (Table 3, Fig. 2A), though were not risk factors in never smokers (Table 3, Fig. 2B). However, when divided by age (younger, <70 vs. older, 70), therapeutic modality did not affect the incidence rate of secondary BC (Supplementary Fig. 1A and B). Comment Several studies using Surveillance, Epidemiology, and End Results (SEER) database and UCSF Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database suggested that radiotherapy for prostate cancer can induce secondary BC (3 10). In contrast, several studies using smaller cohorts failed to show a significant increased risk of secondary BC (21 23). Consistent with these findings, the present study showed a marginal increased risk of secondary BC after EBRT for prostate cancer compared with RP, probably because of the small sample size. Boorjian et al. reported the impact of smoking on BC incidence among men with prostate cancer using the CaPSURE database (9), and showed increased risk of BC incidence with treatment with radiotherapy of ~2-fold compared with RP and smoking status also increased BC incidence risk ~2-fold. Furthermore, radiotherapy and presence of smoking in combination increased the incidence rate of BC ~4-fold. Similarly, this study showed the promoting effect on BC incidence by EBRT and smoking history, as well as a combinational effect of radiotherapy and smoking history. The consistent result in both studies from the USA and Japan as well as by a populationbased database and single institution database suggested the robustness of the finding that smoking history increases the BC incidence in combination with radiotherapy. Furthermore, in addition to current smoking status indicated by Boorjian et al. (9), this study has shown that smoking history was also a risk factor of secondary BC after EBRT for prostate cancer. Previous studies in breast cancer and Hodgkin s lymphoma showed that smoking and radiotherapy in combination increased the risk of secondary lung cancer (24,25). Thus, smoking status may be helpful in choosing the therapeutic options for prostate cancer, indicating that smokers may be better to undergo RP instead of radiotherapy. However, age may not be informative in the selection between radiotherapy or RP in terms of secondary BC. Most cancer including BC can be induced by the accumulation of genetic mutations by various environmental stimuli. Both irradiation and cigarette smoking are known to cause genetic mutations by their genotoxic effects. Therefore, such genotoxic effects in the bladder may synergistically increase genetic aberrations, resulting in the increased incidence of BC. Smoking history affected the BC incidence, which may be accounted for by the hypothesis that tumorinitiated region by smoking can be promoted by irradiation, but not vice versa. This hypothesis can be supported by the promoting role of irradiation, as irradiation-induced BC has been reported to be associated with aggressive phenotype (26,27). In contrast, smoking Table 2. Associations between parameters and comorbidity with secondary BC according to therapeutic modality Variable EBRT + RP EBRT RP HR 95% CI P value HR 95% CI P value HR 95% CI P value Age (per unit) a a Ever smoking No Yes a a Current smoking No Yes Therapeutic modality RP 1 EBRT HR, hazard ratio; CI, confidence interval. a Statistically significant.
4 Jpn J Clin Oncol, 2016, Vol. 46, No Figure 1. Secondary bladder cancer (BC)-free survival rates in patients with prostate cancer according to smoking status. (A) and (B) Secondary BC-free survival rate in patients treated with EBRT stratified by ever smoking (A) and current smoking (B). (C) and (D) Secondary BC-free survival rate in patients treated with RP stratified by ever smoking (C) and current smoking (D). Table 3. Associations between clinicopathological parameters and comorbidity with secondary BC according to smoking history Variable Ever smoker Never smoker HR 95% CI P value HR 95% CI P value Age (per unit) a Current smoking No 1 Yes Therapeutic modality RP 1 1 EBRT a a Statistically significant. is a risk factor of BC incidence, but not related to recurrence, progression and motility (28,29). The present study had several limitations. For instance, the study design was retrospective, the sample size was relatively small, and the follow-up period was relatively short. In addition, this study lacks the information about the smoking year and smoking amount. Also, detection bias by symptoms such as gross-hematuria and bladder irritation, which are often caused by radiotherapy, may have affected the results. Selection bias of therapy for prostate cancer may also have affected the results. Conversely, this study included a cohort from the urological department from single institution, assuring high integrity of the data, in contrast to data from registry databases. Taken together, these findings revealed that cigarette smoking may increase comorbid risk with secondary BC in men with prostate cancer treated with EBRT, but not with RP, which suggests that smoking history might be one of criteria to choose RP than EBRT, whereas age would not be a criterion for therapeutic selection in terms of secondary BC. Supplementary data Supplementary data are available at org. Acknowledgements We would like to thank Dr Junji Kishimoto for consulting about statistical analyses and the Edanz Group Japan for editorial assistance.
5 956 Smoking effect on secondary bladder cancer Figure 2. Secondary BC-free survival rates in patients with prostate cancer according to therapeutic modality. (A) and (B) Secondary BC-free survival rate in men with (A) or without (B) smoking history stratified by therapeutic modality. Funding This work was supported by Kakenhi grants ( and ) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Medical Research Promotion Grant from Takeda Science Foundation, Research Promotion Grant from Daiwa Securities Health Foundation, and Research Promotion Grant from Smoking Research Foundation. Conflict of interest statement None declared. References 1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, CA Cancer J Clin 2014;64: Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61: Neugut AI, Ahsan H, Robinson E, et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997;79: Brenner DJ, Curtis RE, Hall EJ, et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88: Moon K, Stukenborg GJ, Keim J, et al. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107: Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;72: Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008;180: Singh AK, Mashtare TL, McCloskey SA, et al. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys 2010;78: Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007;177: Pawlish KS, Schottenfeld D, Severson R, et al. Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate 1997;33: Shiota M, Yokomizo A, Takeuchi A, et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget 2015;6: Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol 2009;27: Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 2012;42: Simonis K, Shariat SF, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol 2014;24: Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 2015;29: Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th edn. Hoboken: John Wiley & Sons Inc, Sasaki T, Nakamura K, Shioyama Y, et al. Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report. Jpn J Clin Oncol 2004;34: Arimura H, Itano W, Shioyama Y, et al. Computerized estimation of patient setup errors in portal images based on localized pelvic templates for prostate cancer radiotherapy. J Radiat Res 2012;53: Shiota M, Yokomizo A, Takeuchi A, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol 2014;110: Eble JN, Sauter G, Epstein JE, et al. Tumours of the Urinary System and Male Genital Organs (World Health Organization Classification of Tumours). Lyon: IARC Press, Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 2005;174: Movsas B, Hanlon AL, Pinover W, et al. Is there an increased risk of second primaries following prostate irradiation?. Int J Radiat Oncol Biol Phys 1998;41: Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, Radiother Oncol 2002;65: Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin s disease. J Natl Cancer Inst 2002;94: Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26:392 8.
6 Jpn J Clin Oncol, 2016, Vol. 46, No Yee DS, Shariat SF, Lowrance WT, et al. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 2010;183: Bostrom PJ, Soloway MS, Manoharan M, et al. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol 2008;179: Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65: Grotenhuis AJ, Ebben CW, Aben KK, et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol 2015;33:65.e9 17.
Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationA rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases
MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationradiotherapy: A JROSG surveillance Author(s) Kozuka, Takuyo; Nakajima, Nobuaki; Akimoto, Tetsuo Citation Journal of Radiation Research (2015
Current status and outcomes of pati Titlerecurrence after prostatectomy who radiotherapy: A JROSG surveillance Mizowaki, Takashi; Aoki, Manabu; Na Author(s) Yorozu, Atsunori; Kokubo, Masaki; K Kozuka,
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationPercentage of patients who underwent endoscopic procedures following SWL
Non-QPP Measures Measure ID Measure Title Definition Type Domain 1 AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis Percentage of patients with NEW diagnosis of clinically significant
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationRadical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report
Jpn J Clin Oncol 2003;33(3)122 126 Original Articles Radical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report Katsumasa Nakamura 1, Teruki Teshima 2, Yutaka Takahashi 2,
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationQuestions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test
Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationResearch Article Gross Hematuria in Patients with Prostate Cancer: Etiology and Management
ISRN Surgery Volume 2013, Article ID 685327, 4 pages http://dx.doi.org/10.1155/2013/685327 Research Article Gross Hematuria in Patients with Prostate Cancer: Etiology and Management Ofer N. Gofrit, 1 Ran
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationRisk Factors for Loss to Follow-up During Active Surveillance of Patients with Stage I Seminoma
Jpn J Clin Oncol 2014;44(4)355 359 doi:10.1093/jjco/hyu001 Advance Access Publication 20 February 2014 Risk Factors for Loss to Follow-up During Active Surveillance of Patients with Stage I Seminoma Tsuyoshi
More informationEffective Health Care Program
Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationChapter 18: Glossary
Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationPrimary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature
ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationRadiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors
Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Yoshiyuki Shioyama 1, Katsumasa Nakamura 1, Saiji Ohga 1, Satoshi Nomoto 1, Tomonari Sasaki 1, Toshihiro
More information1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.
ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in
More information